Myelodysplastic Syndromes (MDS)
Conditions
Keywords
Myelodysplastic syndromes (MDS)
Brief summary
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.
Interventions
DRUGPrescribed treatments for myelodysplastic syndromes (MDS)
According to the product label
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants: * Aged at least 18 years at initial diagnosis of MDS * Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and * Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate Inclusion criteria for the prospective enrolment of MDS participants: * Aged at least 18 years at initial diagnosis of MDS; and * Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and * Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate
Exclusion criteria
• None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Participant sex | Baseline |
| Participant drinking status | Baseline |
| Family history of MDS or other hematopoietic cancers | Baseline |
| Participant myelodysplastic syndromes diagnosis information | Baseline |
| Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis | Baseline |
| Participant comorbidities at diagnosis | Baseline |
| Participant Charlson comorbidity index (CCI) score at diagnosis | Baseline |
| Prior clinical diagnosis of other cancers | Baseline |
| Prior clinical diagnosis of hematological diseases | Baseline |
| Anemia status at diagnosis | Bseline |
| Thrombocytopenia status at diagnosis | Baseline |
| Neutropenia status at diagnosis | Baseline |
| Iron overload status at diagnosis | Baseline |
| Red blood cell (RBC) transfusion dependence status at diagnosis | Baseline |
| International Prognostic Scoring System (IPSS) score at diagnosis | Baseline |
| Revised International Prognostic Scoring System (IPSS-R) score at diagnosis | Baseline |
| Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis | Baseline |
| Bone marrow aspirate results | Baseline and up to 2-years |
| Presence of dysplasia | Baseline and up to 2-years |
| Cytogenetic test results | Baseline and up to 2-years |
| Mutation test results at diagnosis | Baseline |
| Complete blood count test results at diagnosis | Baseline |
| Mean corpuscular volume (MCV) | Baseline and up to 2-years |
| C-reactive protein (CRP) | Baseline and up to 2-years |
| Serum ferritin (SF) level | Baseline and up to 2-years |
| Serum erythropoietin levels | Baseline and up to 2-years |
| Lactate dehydrogenase (LDH) | Baseline and up to 2-years |
| Participant race | Baseline |
| Participant weight | Baseline |
| Participant height | Baseline |
| Participant body mass index (BMI) | Baseline |
| Participant age | Baseline |
| Participant smoking status | Baseline |
Secondary
| Measure | Time frame |
|---|---|
| Time to disease-risk progression (per IPSS-R) | Baseline and up to 2-years |
| Time to acute myeloid leukemia (AML) progression | Baseline and up to 2-years |
| Time to iron overload | Baseline and up to 2-years |
| Overall response rate (ORR) | Baseline and up to 2-years |
| Duration of response (DOR) | Baseline and up to 2-years |
| Real-world relapse-free survival (rwRFS) | Baseline and up to 2-years |
| Initial treatment received following diagnosis | Baseline |
| Prior treatments and concomitant medications received | Baseline |
| Subsequent treatments received | Up to 2-years |
| Time from diagnosis to treatment initiation | Baseline |
| Treatment duration | Up to 2-years |
| Real-world overall survival (rwOS) | Baseline and up to 2-years |
Countries
Singapore, South Korea, Taiwan
Contacts
CONTACTBMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACTFirst line of the email MUST contain NCT # and Site #.
STUDY_DIRECTORBristol Myers Squibb
Bristol-Myers Squibb
STUDY_DIRECTORBristol-Myers Squibb
Bristol-Myers Squibb
Outcome results
None listed